Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

Published on :

Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant IND clearance validates Company’s Artificial Immune Modulation [….]

Serial Entrepreneurs of the Biohealth Capital Region

Published on :

Serial Entrepreneurs of the Biohealth Capital Region A strong group of entrepreneurs ready and willing to innovate, fund and lead new bioscience companies is essential to the creation and sustainability of top-tier biohealth clusters.  It is often referenced that the BioHealth Capital Region (BHCR) lacks a deep enough pool of qualified executive talent that is [….]